Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11333989 | 0.76 | MAPT (0.63) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4249157 | 0.75 | ALDH1A1 (0.48) | MAPTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5534934 | 0.73 | AHR (0.46) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL341904 | 0.73 | KDM4E (0.47) | MAPTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4071987 | 0.71 | CHRM5 (0.37) | NPC1RAB9ASMN1; SMN2MAPK1NOTUM | |
| SCHEMBL2582425 | 0.68 | AHR (0.43) | MAPTKMT2AKDM4EAHR | |
| SCHEMBL69423 | 0.68 | MAOB (0.55) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3434341 | 0.67 | MAPT (0.82) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6076176 | 0.67 | AHR (0.54) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL429962 | 0.66 | MAOB (0.42) | MAPTMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590944-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MAPT 4518/4885MEN1 1081/4885KMT2A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.